Could a triple therapy tackle diabetes, high blood pressure, and arthritis at once?

NCT ID NCT03686657

First seen Jul 16, 2026 · Last updated Jul 17, 2026 · Updated 1 time

Summary

This study investigates whether adding two common drugs—valsartan (for high blood pressure) and celecoxib (for arthritis pain)—to standard metformin therapy can improve blood sugar control in people with type 2 diabetes. The trial enrolls adults with obesity, high blood pressure, and arthritis who are not well-controlled on metformin alone. Over 26 weeks, researchers will measure changes in blood sugar, insulin function, and inflammation to see if the triple combination works better than metformin by itself.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance
a combination of valsartan, celecoxib, and metformin (called RK-01)
What this could lead to
If successful, this could point toward a more effective treatment for type 2 diabetes that also addresses related conditions like high blood pressure and arthritis.
What could go wrong
This is an early-stage proof-of-concept study with a small number of participants, so results may not apply broadly. The combination of drugs also carries risks like kidney or stomach issues.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ARTHRITIS are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • Albany Medical College

    Albany, New York, 12206, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.